Evidence map›Paper›PMID 30464437›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Outcomes for symptomatic non-obstructed individuals and individuals with mild (GOLD stage 1) COPD in a population based cohort.

Rogelio Perez-Padilla, Fernando C Wehrmeister, Maria Montes de Oca, Maria Victorina Lopez, Jose R Jardim, Adriana Muiño, Gonzalo Valdivia, Ana Maria B Menezes

Open access · goldAbstract readComparative StudyMulticenter Study
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Early diagnosis of COPD: myth or a true perspective.European respiratory review : an official journal of the European Respiratory Society · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 6 countries.

Rogelio Perez-PadillaNational Institute of Respiratory Diseases, Mexico City, Mexico, perezpad@gmail.com.
Fernando C WehrmeisterFederal University of Pelotas, Pelotas, Brazil.
Maria Montes de OcaPulmonary Division, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela.
Maria Victorina LopezFaculty of Medicine, University of the Republic, Montevideo, Uruguay.
Jose R JardimFederal University of Sao Paulo, Sao Paulo, Brazil.
Adriana MuiñoFaculty of Medicine, University of the Republic, Montevideo, Uruguay.
Gonzalo ValdiviaPontificia Universidad Catolica de Chile, Santiago, Chile.
Ana Maria B MenezesFederal University of Pelotas, Pelotas, Brazil.
Universidad de la República de Uruguay · UYUniversidade Federal de Pelotas · BRHospital Clínico Universitario de Caracas · VEPontificia Universidad Católica de Chile · CLUniversidade Federal de São Paulo · BRVietnam National Children's Hospital · VN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to study the adverse outcomes of symptomatic and asymptomatic non-obstructed individuals and those with mild COPD longitudinally in participants from three Latin-American cities.

methodsTwo population-based surveys of adults with spirometry were conducted for these same individuals with a 5- to 9-year interval. We evaluated the impact of respiratory symptoms (cough, phlegm, wheezing or dyspnea) in non-obstructed individuals, and among those classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1, COPD on exacerbation frequency, mortality and FEV

resultsNon-obstructed symptomatic individuals had a marginal increased risk of mortality (HR 1.3; 95% CI 0.9-1.94), increased FEV

conclusionsThe presence of respiratory symptoms in non-obstructed individuals was a predictor of mortality, lung-function decline and exacerbations, whereas the impact of GOLD stage 1 was mild and inconsistent. Respiratory symptoms were associated with asthma, current smoking, and the report of heart disease. Spirometric case-finding and treatment should target individuals with moderate-to-severe airflow obstruction and those with restriction, the groups with consistent increased mortality.

Indexed as

AdultAgedAsthmaDisease ProgressionFemaleForced Expiratory VolumeHumansLungMaleMexicoMiddle AgedPrognosisPulmonary Disease, Chronic ObstructiveRisk FactorsSeverity of Illness IndexSmokingairflow obstructionCOPDCOPD exacerbationslung function declinemild COPDscreening for COPDspirometry

Identifiers

PMID30464437
PMCPMC6208535
OpenAlexW2898094874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.